Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J. Kader AK, et al. Among authors: mcconnell jd. Eur Urol. 2012 Dec;62(6):953-61. doi: 10.1016/j.eururo.2012.05.006. Epub 2012 May 12. Eur Urol. 2012. PMID: 22652152 Free PMC article.
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, Schellhammer PF, Bruskewitz R, Matsumoto AM, Harrison LH, Fuselier HA, Walsh P, Roy J, Andriole G, Resnick M, Waldstreicher J. Roehrborn CG, et al. J Urol. 2000 Jan;163(1):13-20. J Urol. 2000. PMID: 10604304 Clinical Trial.
Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J. Roehrborn CG, et al. Among authors: mcconnell jd. Urology. 1999 Mar;53(3):473-80. doi: 10.1016/s0090-4295(98)00654-2. Urology. 1999. PMID: 10096369 Clinical Trial.
Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.
Roehrborn CG, McConnell JD, Saltzman B, Bergner D, Gray T, Narayan P, Cook TJ, Johnson-Levonas AO, Quezada WA, Waldstreicher J; PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Roehrborn CG, et al. Among authors: mcconnell jd. Eur Urol. 2002 Jul;42(1):1-6. doi: 10.1016/s0302-2838(02)00210-5. Eur Urol. 2002. PMID: 12121721 Clinical Trial.
97 results